Medical 21 has filed a notice of an exempt offering of securities to raise $10,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Medical 21 is raising $10,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Manny Villafana played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Medical 21
Medical 21, Inc. is a developmental stage medical device company founded by Dr. Manny Villafaa and located in Minneapolis, MN. We are developing and intend to commercialize and market an artificial graft to bypass blockages in the heart. With roughly one million heart bypass surgeries performed each year worldwide and cardiovascular disease as the #1 cause of death globally, clinicians need a better option for a complete revascularization procedure of the heart. Our MAVERICS graft is a small-diameter flexible tube encased in a nitinol scaffold that eliminates the need to harvest blood vessels from the patient’s legs, arms, and chest. This leads to a higher quality of life for the patient through less pain, decreased procedure and recovery time, and lower risk of infection and complications. By eliminating the need to harvest vessels from a patient’s arm, leg, and chest, surgical teams can save time and help patients who can then recover faster without additional scarring, pain, or post-op complications. Our revolutionary artificial graft allows those who currently cannot have bypass surgery — such as people with amputations, severe diabetes, or varicose veins — to be considered for the procedure.
To learn more about Medical 21, visit http://www.medical21.com/
Contact:
Manny Villafana, Chief Executive Officer
612-670-5507
https://www.linkedin.com/in/manny-villafana-0451231a9/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.